
Cinnarizine
0,025 g № 25, № 50
Group of action
Active ingredient
Dosage form
Tablets
ATC code
N07CA02
RX/OTC
RX
Marketing authorisation no.
UA/3384/01/01
General properties
Pharmacotherapeutic group
Agents, used for vestibular disorders.
Indications
Disorders of cerebral circulation:
- symptomatic treatment of cerebrovascular disorders including vertigo, ringing in the ears (tinnitus), headache vascular origin, irritability, memory loss and inability to concentrate;
- migraine prophylaxis.
Peripheral circulatory disorders:
- Symptomatic treatment of peripheral vascular disorders including Raynaud's disease, akrocyanosis, intermittent claudication, trophic disorders, trophic and varicose ulcers, paresthesia, nocturnal cramps in the limbs, cold limbs.
Balance disorders:
- symptomatic treatment of labyrinth disorders including vertigo, tinnitus, nystagmus, nausea and vomiting.
Motion Sickness:
- Prevention of motion sickness
Contraindications
Hypersensitivity to the active substance or to any of the excipients of the drug.
Pharmaceutical characteristics
Basic physical and chemical properties
Tablets of white or almost white color.
Shelf life
5 years
Storage conditions
Keep out of reach of children in the original packaging at a temperature not exceeding 25 ° C.
Rx
Manufacturer
PJSC "Lekhim-Kharkiv"
Location
36, Severyna Pototskoho St., 61115 Kharkiv, Ukraine